| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RB1 |
| Uniprot No | P06400 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 769-921aa |
| 氨基酸序列 | LQYASTRPPTLSPIPHIPRSPYKFPSSPLRIPGGNIYISPLKSPYKISEGLPTPTKMTPRSRILVSIGESFGTSEKFQKINQMVCNSDRVLKRSAEGSNPPKPLKKLRFDIEGSDEADGSKHLPGESKFQQKLAEMTSTRTRMQKQKMNDSMD |
| 预测分子量 | 24.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于RB1重组蛋白的文献摘要信息，供参考：
---
1. **文献名称**：*Production and functional characterization of recombinant retinoblastoma protein (RB1) for cell cycle studies*
**作者**：Lee S, et al.
**摘要**：研究报道了在大肠杆菌中高效表达并纯化人源RB1重组蛋白的方法，通过体外磷酸化实验验证其与CDK4/cyclin D复合物的相互作用，证实重组RB1能抑制E2F转录活性，为细胞周期调控机制研究提供工具。
---
2. **文献名称**：*Structural analysis of recombinant RB1 C-terminal domain reveals phosphorylation-dependent conformational changes*
**作者**：Zhang Y, et al.
**摘要**：通过X射线晶体学解析了RB1重组蛋白C端结构域的三维构象，发现磷酸化修饰导致其与E2F1的结合能力显著下降，揭示了RB1在肿瘤发生中构效关系的关键机制。
---
3. **文献名称**：*Development of a mammalian cell expression system for high-yield RB1 production*
**作者**：Müller P, et al.
**摘要**：开发了一种基于HEK293细胞的真核表达系统，成功获得高纯度、具有天然构象的全长RB1重组蛋白，并证明其在体外可恢复RB1缺失肿瘤细胞的周期阻滞功能。
---
4. **文献名称**：*Recombinant RB1 as a therapeutic agent in Rb-deficient retinoblastoma models*
**作者**：Chen H, et al.
**摘要**：利用腺病毒载体递送重组RB1蛋白至视网膜母细胞瘤细胞，证实其能诱导细胞凋亡并抑制肿瘤生长，为基因治疗提供了实验依据。
---
注：以上文献信息为模拟示例，实际引用请以真实发表的论文为准。建议通过PubMed或Web of Science检索关键词“recombinant RB1 protein”获取具体文献。
RB1 recombinant protein is derived from the retinoblastoma 1 (RB1) gene, a critical tumor suppressor that regulates cell cycle progression and maintains genomic stability. The RB1 gene encodes the retinoblastoma protein (pRB), which functions primarily by binding and inhibiting E2F transcription factors, thereby blocking the transition from the G1 to S phase of the cell cycle. Loss or mutation of RB1 disrupts this regulatory mechanism, leading to uncontrolled cell proliferation and tumorigenesis. RB1 mutations are strongly associated with retinoblastoma, a rare childhood eye cancer, as well as osteosarcomas, bladder cancers, and other malignancies.
Recombinant RB1 protein is produced using molecular cloning techniques, where the RB1 gene is inserted into expression vectors (e.g., bacterial, mammalian, or insect cell systems) to enable large-scale production. This engineered protein retains the functional domains of native pRB, allowing researchers to study its interactions with E2F proteins, chromatin-modifying enzymes, and viral oncoproteins like HPV E7. Its purity and activity are validated through methods such as SDS-PAGE, Western blotting, and functional assays.
In research, RB1 recombinant protein serves as a tool to investigate cell cycle regulation, tumor suppressor mechanisms, and cancer therapy resistance. It aids in screening drugs targeting RB1 pathway components or restoring pRB function in RB1-deficient cancers. Additionally, it supports structural studies to map binding interfaces or analyze disease-linked mutations. By providing a standardized, high-quality reagent, recombinant RB1 accelerates both basic research and translational applications in oncology and molecular biology.
×
